On May 6, news emerged that Hangzhou Nanoxica Electronic Technology Co., Ltd. has recently concluded a strategic financing round worth RMB 300 million. This round was co-led by prominent industrial investment institutions and Legend Capital, with substantial follow-on investment (hereafter referred to as "oversubscribed follow-up investment") from Forebright Capital. Additionally, GF Xinde Investment and Caitong Capital also participated in this funding round. The proceeds from this financing will be earmarked for accelerating clinical trials and refining the core technologies of visual brain-computer interface products.

Established in 2014, Nanoxica is dedicated to the research, development, production, and sales of brain-computer interfaces and neurobiological chips. The company has successfully launched two innovative products: the retinal pathway brain-computer interface, known as E-BCI, and the visual cortex pathway brain-computer interface, V-BCI. These products boast an impressive maximum of 1,280 signal acquisition and stimulation channels. All the underlying technologies are independently developed by Nanoxica, with core performance indicators leading the industry on a global scale. At present, the retinal interface product has commenced human clinical trials, while the visual cortex interface product is slated to begin prospective clinical trials later this year.